Immix Biopharma
IMMX
109 hedge funds and large institutions have $580M invested in Immix Biopharma in 2026 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 35 increasing their positions, 13 reducing their positions, and 11 closing their positions.
309% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 11
230% more call options, than puts
Call options by funds: $1.02M | Put options by funds: $308K
169% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 13
135% more capital invested
Capital invested by funds: $247M → $580M (+$333M)
52.2% more ownership
Funds ownership: 51.12% → 103.33% (+52%)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
42% more funds holding
Funds holding: 77 → 109 (+32)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$26M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$25.7M |
| 3 |
BlackRock
New York
|
+$23.4M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$21.8M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$17.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$4.01M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$2.09M |
| 3 |
BOCH
Blue Owl Capital Holdings
New York
|
-$1.02M |
| 4 |
SEI Investments
Oaks,
Pennsylvania
|
-$740K |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$578K |
IMMX Hedge Fund Activity: Q2 2026 in Review
109 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Immix Biopharma (IMMX) for Q2 2026, worth a combined $580M — up 135% from $247M a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new IMMX positions and 11 closed out — a net gain of 34 holders — while 35 added to existing stakes and 13 trimmed.
The largest buyer was State Street, adding an estimated $26M. The largest seller was Susquehanna International Group, cutting an estimated $4.01M.
- 109 institutional investors held Immix Biopharma (IMMX) as of Q2 2026, up from 77 in Q1 2026.
- Funds reported $580M of Immix Biopharma stock for Q2 2026, up 135% quarter-over-quarter.
- 45 funds opened new Immix Biopharma positions in Q2 2026 and 11 closed out, a net change of +34 holders.
- The largest Immix Biopharma buyer in Q2 2026 was State Street, an estimated $26M added.
- The largest Immix Biopharma seller in Q2 2026 was Susquehanna International Group, an estimated $4.01M sold.
Based on aggregated 13F filings for Q2 2026.